Boudreau Ryan L, Davidson Beverly L
Program in Gene Therapy, Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA.
Curr Top Dev Biol. 2006;75:73-92. doi: 10.1016/S0070-2153(06)75003-7.
RNA interference (RNAi) mediates gene silencing in a sequence-specific manner and has proven to be an exceptionally valuable discovery for bench scientists. In the laboratory, RNAi technologies provide efficient means for validating drug targets and for performing reverse genetics to study gene function (Friedman and Perrimon, 2004). Patients may also benefit from RNAi as applications extend to potential human therapies. RNAi-based treatments are being investigated and may provide hope for patients suffering from cancer, viral infections, or genetic diseases for which effective therapies are currently lacking. Notably, several independent studies have demonstrated that RNAi therapy can improve disease phenotypes in various mouse models of human disease. In this chapter, we focus on the potential of RNAi in treating neurologic diseases for which reduction of mutant or toxic gene expression may provide therapeutic benefit. We discuss approaches to achieving RNAi in vivo, progress in the field, and the potential pitfalls associated with RNAi-based therapies.
RNA干扰(RNAi)以序列特异性方式介导基因沉默,并且已被证明是实验室科学家一项极其有价值的发现。在实验室中,RNAi技术为验证药物靶点和进行反向遗传学研究基因功能提供了有效的手段(Friedman和Perrimon,2004年)。随着RNAi应用扩展到潜在的人类治疗领域,患者也可能从中受益。基于RNAi的治疗方法正在研究中,对于目前缺乏有效治疗方法的癌症、病毒感染或遗传疾病患者而言,可能带来希望。值得注意的是,几项独立研究已证明,RNAi疗法可改善多种人类疾病小鼠模型中的疾病表型。在本章中,我们重点关注RNAi在治疗神经疾病方面的潜力,其中减少突变或毒性基因表达可能带来治疗益处。我们讨论了在体内实现RNAi的方法、该领域的进展以及基于RNAi疗法相关的潜在陷阱。